Company Profile

Zebra Biologics Inc
Profile last edited on: 12/21/21      CAGE: 7Z6E5      UEI: MGBMJBJ59E65

Business Identifier: Bio-superior agonist and antagonist antibody therapeutics
Year Founded
2013
First Award
2019
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1041 Old Marlboro Road
Concord, MA 01742
   (978) 318-0076
   N/A
   www.zebrabiologics.com
Location: Single
Congr. District: 03
County: Middlesex

Public Profile

Advancing an internal portfolio of novel full human agonist antibodies and novel highly selective ion-channel blockers, Zebra Boilogics is a pre-clinical stage biopharmaceutical company pioneering development of platform technologies to allow cellular function-based screening for the discovery and selection of fully human therapeutic biologics (antibodies, peptides or proteins) from DNA-encoded combinatorial libraries of human antibodies, peptides or “protein-in-proteins”. Zebra Biologics olds an exclusive licenses from the The Scripps Research Institute both to the core platform technology and to current and future candidate therapeutics derived from the platform. Applicable for lead discovery across all therapeutic areas and all receptor classes, Zebra has optimized the platform for the highly desirable feature of allowing selection of rare agonist antibodies from very large combinatorial librari

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $308,708
Project Title: Engineering a long-acting relaxin agonist to treat liver fibrosis
2020 1 NIH $210,578
Project Title: Treatment of Diabetic Retinopathy with TRKB Agonist Antibodies
2019 1 NIH $304,258
Project Title: Discovery of TrkC Agonist Antibodies for Hearing Loss

Key People / Management

  Ronald M Lindsay -- Founder and Chief Executive Officer

  Peter S Distefano -- Founder and CSO

  Phillip Frost -- Founder

  Paul Greengard -- Founder

  Richard A Lerner -- Founder